RxDoctor Payments Data

Mark Schecker, MD

Allergy · Myrtle Beach, SCNPI 1023014057

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.3% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Optinose US, Inc. at 32.7% of the total.

$392in general payments, 2019–2025

Across 5 payments — averaging $78.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$128
  • AstraZeneca$125
  • GSK$65
  • Octapharma USA, Inc.$40
  • Amgen$34

What the payments were for

  • Food & beverage$35891%
  • Education$349%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Optinose US, Inc.1$128
AstraZeneca1$125
GSK1$65
Octapharma USA, Inc.1$40
Amgen1$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$229,460
Medicare patients
659
Services billed
18,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter132$114,495
Dupixent SyringeDupilumab18$88,721
Breo ElliptaFluticasone/Vilanterol148$71,258
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$45,789
Spiriva RespimatTiotropium Bromide32$37,951
Arnuity ElliptaFluticasone Furoate92$23,059
SymbicortBudesonide/Formoterol Fumarate59$20,456
Advair HfaFluticasone Propion/Salmeterol42$17,568
Ipratropium Bromide327$17,200
Azelastine Hcl326$11,927
Olopatadine Hcl103$11,353
Incruse ElliptaUmeclidinium Bromide17$9,607
Mometasone Furoate38$8,997
Fluticasone Propionate378$8,896
Epinephrine40$6,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$65$218,418389 claims
AstraZenecaBreztri Aerosphere, Symbicort$125$66,245106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other allergy in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →